<DOC>
	<DOC>NCT02125071</DOC>
	<brief_summary>An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.</brief_summary>
	<brief_title>Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Male or female â‰¤18 years old Patients who understand the informed consent form and signed the form voluntarily Patients who underwent liver transplantation due to HBV related disease and will be treated for prevention of hepatitis B relapse after liver transplantation Multiorgan recipient or reimplantation IgA Deficiency Serious nephropathy Serious cardiovascular system failure within 6 months Ischemic or hemolytic anemia Condition of immunosuppression and immunodeficiency Hypersensitivity or allergic to blood products HIV or HCV positive Participation to other clinical trial within 3 months Pregnancy or breast feeding Those who the investigator determines inappropriate to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>